Showing items 1 - 2 of 2

Your selections:

Factors associated with adverse cardiovascular events in cancer patients treated with bevacizumab

- Ngo, Doan T. M., Williams, Trent, Horder, Sophie, Kritharides, Leonard, Vardy, Janette, Mandaliya, Hhiren, Nordman, Ina I. C., Lynam, James, Bonaventura, Tony, Sverdlov, Aaron L.

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

- Tebbutt, Niall C., Wilson, Kate, Forgeson, Garry, Cunningham, David, Saunders, Mark P., Stockler, Martin R., Chua, Yujo, Zalcberg, John R., Simes, R. John, Price, Timothy J., Gebski, Val J., Cummins, Michelle M., Zannino, Dianna, van Hazel, Guy A., Robinson, Bridget, Broad, Adam, Ganju, Vinod, Ackland, Stephen P.

  • 1
  • Disclaimer
  • Privacy
  • Copyright
  • Contact
  • Deposit